Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
From BioCentury This Week · · 33 min
This plays from the publisher's own server. We do not host a copy.
Description
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the proposal (https://www.biocentury.com/article/659055), as well as a concession (https://www.biocentury.com/article/659099) for the biopharma industry on first-in-human studies in PDUFA reauthorization negotiations with FDA. The analysts also discuss the latest pair of billion-dollar biotech deals: Gilead's $3.2 billion takeout (https://www.biocentury.com/article/659064) of antibody-drug conjugate company Tubulis and the acquisition of Soleno by Neurocrine for $2.9 billion for its Prader-Willi asset. Finally, BioCentury’s analysts discuss the new $6.3 billion Blackstone Life Sciences fund (https://www.biocentury.com/article/659102) and the €1 billion vehicle unveiled (https://www.biocentury.com/article/659049) last week by European VC Jeito Capital. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech (https://www.iqviabiotech.com/).
View full story: https://www.biocentury.com/article/659127
#FDA #FirstInHuman #BiotechMergers #BiotechInvesting #LifeSciencesVC
00:01 - Sponsor Message: IQVIA Biotech 03:24 - FDA First-in-Human 11:44 - America First PDUFA Policy 17:43 - Gilead Buying Tubulis 23:41 - Blackstone's New Fund 28:37 - Jeito Capital 30:44 - Parker Institute
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)